Hepatic ROS Mediated Macrophage Activation Is Responsible for Irinotecan Induced Liver Injury

Irinotecan is the first line chemotherapy drug used for treatment of metastatic colorectal cancer worldwide. There is increasing evidence suggesting that liver damage, including steatosis and steatohepatitis, can be caused during the treatment involving irinotecan. However, molecular mechanisms by w...

Full description

Bibliographic Details
Main Authors: Bohao Liu, Cong Ding, Wenbin Tang, Chen Zhang, Yiying Gu, Zhiqiang Wang, Tingzi Yu, Zhuan Li
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/11/23/3791
_version_ 1827643275078533120
author Bohao Liu
Cong Ding
Wenbin Tang
Chen Zhang
Yiying Gu
Zhiqiang Wang
Tingzi Yu
Zhuan Li
author_facet Bohao Liu
Cong Ding
Wenbin Tang
Chen Zhang
Yiying Gu
Zhiqiang Wang
Tingzi Yu
Zhuan Li
author_sort Bohao Liu
collection DOAJ
description Irinotecan is the first line chemotherapy drug used for treatment of metastatic colorectal cancer worldwide. There is increasing evidence suggesting that liver damage, including steatosis and steatohepatitis, can be caused during the treatment involving irinotecan. However, molecular mechanisms by which irinotecan-induced liver injury remain elusive. In this study, we found that irinotecan treatment caused significant elevation of ALT, inflammation, and fat accumulation in the liver, which are associated with hepatic macrophage activation. Depletion of macrophages by clodronate liposome improved irinotecan induced liver injury and inflammatory response in mice. In vitro data indicated that irinotecan induced intracellular ROS production in primary hepatocyte and upregulating of toll-like receptor (TLRs) family expression in macrophages. Supernatant from irinotecan treated hepatocyte triggered macrophage activation and upregulation of TLRs in macrophage, and N-acetylcysteine (NAC) abolished these effects. By using co-culture system, we further revealed that irinotecan activated macrophage induced impairment of lipid metabolism and promoted apoptosis in hepatocyte and NAC prevented macrophage-induced cell death and partially revered impaired lipid metabolism in hepatocytes. By using the irinotecan liver injury model, we demonstrated that combining NAC with irinotecan prevented irinotecan-induced macrophage activation, TLR upregulation, liver injury, and partially prevented the accumulation of triglycerides in liver. Our results thus indicated that macrophages play a critical role in irinotecan-induced liver injury, and targeting ROS provides new options for development of hepatoprotective drugs in clinical practice.
first_indexed 2024-03-09T17:51:11Z
format Article
id doaj.art-353e2be1320647eab2140759f4546a33
institution Directory Open Access Journal
issn 2073-4409
language English
last_indexed 2024-03-09T17:51:11Z
publishDate 2022-11-01
publisher MDPI AG
record_format Article
series Cells
spelling doaj.art-353e2be1320647eab2140759f4546a332023-11-24T10:43:52ZengMDPI AGCells2073-44092022-11-011123379110.3390/cells11233791Hepatic ROS Mediated Macrophage Activation Is Responsible for Irinotecan Induced Liver InjuryBohao Liu0Cong Ding1Wenbin Tang2Chen Zhang3Yiying Gu4Zhiqiang Wang5Tingzi Yu6Zhuan Li7The Key Laboratory of Model Animals and Stem Cell Biology in Hunan Province, Hunan Normal University School of Medicine, Changsha 410013, ChinaThe Key Laboratory of Model Animals and Stem Cell Biology in Hunan Province, Hunan Normal University School of Medicine, Changsha 410013, ChinaThe Key Laboratory of Model Animals and Stem Cell Biology in Hunan Province, Hunan Normal University School of Medicine, Changsha 410013, ChinaThe Key Laboratory of Model Animals and Stem Cell Biology in Hunan Province, Hunan Normal University School of Medicine, Changsha 410013, ChinaThe Key Laboratory of Model Animals and Stem Cell Biology in Hunan Province, Hunan Normal University School of Medicine, Changsha 410013, ChinaThe Key Laboratory of Model Animals and Stem Cell Biology in Hunan Province, Hunan Normal University School of Medicine, Changsha 410013, ChinaThe Key Laboratory of Model Animals and Stem Cell Biology in Hunan Province, Hunan Normal University School of Medicine, Changsha 410013, ChinaThe Key Laboratory of Model Animals and Stem Cell Biology in Hunan Province, Hunan Normal University School of Medicine, Changsha 410013, ChinaIrinotecan is the first line chemotherapy drug used for treatment of metastatic colorectal cancer worldwide. There is increasing evidence suggesting that liver damage, including steatosis and steatohepatitis, can be caused during the treatment involving irinotecan. However, molecular mechanisms by which irinotecan-induced liver injury remain elusive. In this study, we found that irinotecan treatment caused significant elevation of ALT, inflammation, and fat accumulation in the liver, which are associated with hepatic macrophage activation. Depletion of macrophages by clodronate liposome improved irinotecan induced liver injury and inflammatory response in mice. In vitro data indicated that irinotecan induced intracellular ROS production in primary hepatocyte and upregulating of toll-like receptor (TLRs) family expression in macrophages. Supernatant from irinotecan treated hepatocyte triggered macrophage activation and upregulation of TLRs in macrophage, and N-acetylcysteine (NAC) abolished these effects. By using co-culture system, we further revealed that irinotecan activated macrophage induced impairment of lipid metabolism and promoted apoptosis in hepatocyte and NAC prevented macrophage-induced cell death and partially revered impaired lipid metabolism in hepatocytes. By using the irinotecan liver injury model, we demonstrated that combining NAC with irinotecan prevented irinotecan-induced macrophage activation, TLR upregulation, liver injury, and partially prevented the accumulation of triglycerides in liver. Our results thus indicated that macrophages play a critical role in irinotecan-induced liver injury, and targeting ROS provides new options for development of hepatoprotective drugs in clinical practice.https://www.mdpi.com/2073-4409/11/23/3791irinotecanliver injurychemotherapymacrophage activationROS
spellingShingle Bohao Liu
Cong Ding
Wenbin Tang
Chen Zhang
Yiying Gu
Zhiqiang Wang
Tingzi Yu
Zhuan Li
Hepatic ROS Mediated Macrophage Activation Is Responsible for Irinotecan Induced Liver Injury
Cells
irinotecan
liver injury
chemotherapy
macrophage activation
ROS
title Hepatic ROS Mediated Macrophage Activation Is Responsible for Irinotecan Induced Liver Injury
title_full Hepatic ROS Mediated Macrophage Activation Is Responsible for Irinotecan Induced Liver Injury
title_fullStr Hepatic ROS Mediated Macrophage Activation Is Responsible for Irinotecan Induced Liver Injury
title_full_unstemmed Hepatic ROS Mediated Macrophage Activation Is Responsible for Irinotecan Induced Liver Injury
title_short Hepatic ROS Mediated Macrophage Activation Is Responsible for Irinotecan Induced Liver Injury
title_sort hepatic ros mediated macrophage activation is responsible for irinotecan induced liver injury
topic irinotecan
liver injury
chemotherapy
macrophage activation
ROS
url https://www.mdpi.com/2073-4409/11/23/3791
work_keys_str_mv AT bohaoliu hepaticrosmediatedmacrophageactivationisresponsibleforirinotecaninducedliverinjury
AT congding hepaticrosmediatedmacrophageactivationisresponsibleforirinotecaninducedliverinjury
AT wenbintang hepaticrosmediatedmacrophageactivationisresponsibleforirinotecaninducedliverinjury
AT chenzhang hepaticrosmediatedmacrophageactivationisresponsibleforirinotecaninducedliverinjury
AT yiyinggu hepaticrosmediatedmacrophageactivationisresponsibleforirinotecaninducedliverinjury
AT zhiqiangwang hepaticrosmediatedmacrophageactivationisresponsibleforirinotecaninducedliverinjury
AT tingziyu hepaticrosmediatedmacrophageactivationisresponsibleforirinotecaninducedliverinjury
AT zhuanli hepaticrosmediatedmacrophageactivationisresponsibleforirinotecaninducedliverinjury